{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:31:37Z","timestamp":1781213497502,"version":"3.54.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ijrobp.2019.12.045","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T21:47:04Z","timestamp":1579902424000},"page":"98-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Intensity Modulated Radiation Therapy Plus Etoposide\/Cisplatin for Patients With Limited Advanced Unresectable Thymic Epithelial Tumors: A Prospective Phase 2 Study"],"prefix":"10.1016","volume":"107","author":[{"given":"Xing-Wen","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Tao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuai-Le","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Quan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Qing","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee C.","family":"Ung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Shun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Liang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2808-3234","authenticated-orcid":false,"given":"Kai-Liang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2019.12.045_bib1","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","article-title":"Epidemiology of thymoma and associated malignancies","volume":"5","author":"Engels","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0003-4975(10)62751-8","article-title":"Primary anterior mediastinal tumors in children and adults","volume":"42","author":"Mullen","year":"1986","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 World Health Organization classification of tumors of the thymus: Continuity and changes","volume":"10","author":"Marx","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.athoracsur.2009.08.074","article-title":"Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery","volume":"89","author":"Margaritora","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib5","first-page":"624","article-title":"The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: A clinical study of 273 patients","volume":"94","author":"Okumura","year":"2002","journal-title":"Cancer-Am Cancer Soc"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib6","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.1990.8.8.1419","article-title":"Chemotherapy of invasive thymoma","volume":"8","author":"Fornasiero","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib7","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib8","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"14","author":"Giaccone","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib9","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1999.17.9.2737","article-title":"Treatment of invasive thymoma with single-agent ifosfamide","volume":"17","author":"Highley","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib10","first-page":"2010","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: An intergroup trial","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer-Am Cancer Soc"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group phase II trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib12","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/sj.bjc.6605347","article-title":"A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: Report of a Japan Clinical Oncology Group trial (JCOG 9605)","volume":"101","author":"Kunitoh","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib13","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/annonc\/mdp483","article-title":"Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)","volume":"21","author":"Palmieri","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib14","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib15","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/JTO.0000000000000362","article-title":"Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803","volume":"9","author":"Inoue","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib16","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-14-0968","article-title":"A phase I\/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: A clinical and translational study","volume":"20","author":"Thomas","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib17","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1097\/JTO.0000000000000692","article-title":"A prospective phase II study of cisplatin and cremophorel-free paclitaxel (genexol-pm) in patients with unresectable thymic epithelial tumors","volume":"10","author":"Kim","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib19","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: An intergroup trial","volume":"15","author":"Loehrer","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2003.12.010","article-title":"Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report","volume":"44","author":"Kim","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.bjc.6605731","article-title":"A phase II trial of dose-dense chemotherapy, followed by surgical resection and\/or thoracic radiotherapy, in locally advanced thymoma: Report of a Japan Clinical Oncology Group trial (JCOG 9606)","volume":"103","author":"Kunitoh","year":"2010","journal-title":"Br J Cancer"},{"issue":"36-44","key":"10.1016\/j.ijrobp.2019.12.045_bib22","first-page":"41","article-title":"Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: A phase II, multi-institutional clinical trial","volume":"147","author":"Korst","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3389\/fonc.2013.00330","article-title":"Radiotherapy for thymic carcinoma: Adjuvant, inductive, and definitive","volume":"3","author":"Komaki","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0167-8140(90)90154-O","article-title":"Role of radiation therapy in locally advanced thymoma","volume":"19","author":"Urgesi","year":"1990","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib25","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/0360-3016(95)00079-E","article-title":"Radiotherapy and chemotherapy for invasive thymomas: A multicentric retrospective review of 90 cases. The FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer","volume":"32","author":"Mornex","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF02743578","article-title":"Radiotherapy for invasive thymoma and thymic carcinoma. Clinicopathological review","volume":"175","author":"Mayer","year":"1999","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib27","first-page":"515","article-title":"Concurrent chemoradiotherapy for unresectable thymic carcinoma","volume":"27","author":"Chen","year":"2004","journal-title":"Chang Gung Med J"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib28","first-page":"2023","article-title":"A pilot study of cisplatin and etoposide with and without radiotherapy for advanced malignant thymoma","volume":"34","author":"Tamiya","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib29","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.21037\/jtd.2017.08.133","article-title":"Chemoradiotherapy for unresectable cases of thymic epithelial tumors: A retrospective study","volume":"9","author":"Kashima","year":"2017","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib30","doi-asserted-by":"crossref","first-page":"S2555","DOI":"10.21037\/jtd.2018.01.154","article-title":"The expanding role of radiation therapy for thymic malignancies","volume":"10","author":"Willmann","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib31","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.4065\/70.11.1053","article-title":"Assessing the interaction of irradiation with etoposide or idarubicin","volume":"70","author":"Haddock","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib32","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/(SICI)1097-0215(19961115)68:4<452::AID-IJC9>3.0.CO;2-#","article-title":"Tumoral platinum concentrations in patients treated with repeated low-dose cisplatin as a radiosensitizer","volume":"68","author":"Lagrange","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0304-3835(96)04140-7","article-title":"Radiosensitizing effect of cisplatin in prostate cancer cell lines","volume":"101","author":"Geldof","year":"1996","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/annonc\/mdx009","article-title":"Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: A multicenter randomized phase III trial","volume":"28","author":"Liang","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib35","first-page":"2485","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer-Am Cancer Soc"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib37","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Vol 2019; 2010. p. 40. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed Feberuary 21, 2020."},{"key":"10.1016\/j.ijrobp.2019.12.045_bib38","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1097\/JTO.0b013e31822e71c0","article-title":"Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma","volume":"6","author":"Agatsuma","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib39","first-page":"706","article-title":"Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma","volume":"68","author":"Macchiarini","year":"1991","journal-title":"Cancer-Am Cancer Soc"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.7326\/0003-4819-129-2-199807150-00006","article-title":"A multidisciplinary approach to therapy for unresectable malignant thymoma","volume":"129","author":"Shin","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib41","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1010-7940(01)00666-2","article-title":"The multimodality treatment of thymic carcinoma","volume":"19","author":"Lucchi","year":"2001","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib42","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1556-0864(15)31586-0","article-title":"Neoadjuvant chemotherapy for stage III and IVA thymomas: A single-institution experience with a long follow-up","volume":"1","author":"Lucchi","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.thorsurg.2008.09.008","article-title":"Multimodality treatment of thymic tumors","volume":"19","author":"Venuta","year":"2009","journal-title":"Thorac Surg Clin"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.cllc.2016.05.019","article-title":"Adjuvant proton beam therapy in the management of thymoma: A dosimetric comparison and acute toxicities","volume":"17","author":"Parikh","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib45","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/cas.12274","article-title":"Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for\u00a0esophageal squamous cell carcinoma","volume":"104","author":"Hara","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib46","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.canlet.2018.01.050","article-title":"Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy","volume":"419","author":"Wu","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib47","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: A single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2019.12.045_bib48","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase ii trial","author":"Cho","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301620300638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301620300638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:46:50Z","timestamp":1759744010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301620300638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0360301620300638"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.12.045","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intensity Modulated Radiation Therapy Plus Etoposide\/Cisplatin for Patients With Limited Advanced Unresectable Thymic Epithelial Tumors: A Prospective Phase 2 Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.12.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}